Jim Dimitroulakos

Summary

Affiliation: Ottawa Health Research Institute
Country: Canada

Publications

  1. pmc Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas
    Jim Dimitroulakos
    Department of Cellular and Molecular Biology, The University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Neoplasia 4:337-46. 2002
  2. ncbi request reprint Activation of the integrated stress response regulates lovastatin-induced apoptosis
    Nima Niknejad
    Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ontario K1H 8L6, Canada
    J Biol Chem 282:29748-56. 2007
  3. pmc Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
    Carly St Germain
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, K1H 8L6, Canada
    Cancer Cell Int 10:32. 2010
  4. ncbi request reprint Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway
    Jim Dimitroulakos
    Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre and Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:4426s-4431s. 2006
  5. pmc Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells
    Laurie Ma
    Centre for Cancer Therapeutics, The Ottawa Hospital Research Institute, Ontario, Canada
    PLoS ONE 7:e46055. 2012
  6. ncbi request reprint Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor
    Angela J Mantha
    Centre for Cancer Therapeutics and Medical Oncology, Ottawa Regional Cancer Centre, Ottawa Health Research Institute, 503 Smyth Road, Ottawa, Ontario, Canada K1H 1C4
    Clin Cancer Res 11:2398-407. 2005
  7. ncbi request reprint Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3
    Anna O'Brien
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Box 926, Ottawa, ON, K1H 8L6, Canada
    Anticancer Res 32:2679-88. 2012
  8. doi request reprint Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status
    Catia Cemeus
    Centre for Cancer Therapeutics, The Ottawa Health Research Institute and Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, ON, Canada, K1H 1C4
    J Neurooncol 90:9-17. 2008
  9. ncbi request reprint Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells
    Angela J Mantha
    Centre for Cancer Therapeutics, Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, Ontario, K1H 1C4, Canada
    J Cancer Res Clin Oncol 129:631-41. 2003
  10. pmc Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3
    Carly St Germain
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Neoplasia 12:527-38. 2010

Collaborators

Detail Information

Publications18

  1. pmc Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas
    Jim Dimitroulakos
    Department of Cellular and Molecular Biology, The University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Neoplasia 4:337-46. 2002
    ..Our data suggest that the depletion of nonsterol mevalonate metabolites, particularly GGPP, can be potential mediators of lovastatin-induced apoptosis of HNSCC and CC cells...
  2. ncbi request reprint Activation of the integrated stress response regulates lovastatin-induced apoptosis
    Nima Niknejad
    Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ontario K1H 8L6, Canada
    J Biol Chem 282:29748-56. 2007
    ..Therefore, lovastatin, by targeting mevalonate synthesis, is a potent inducer of the ISR through a novel and as yet unrecognized mechanism...
  3. pmc Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
    Carly St Germain
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, K1H 8L6, Canada
    Cancer Cell Int 10:32. 2010
    ..In this study, we evaluated the role of ATF3 in regulating the co-operative cytotoxicity of cisplatin in combination with an HDAC inhibitor...
  4. ncbi request reprint Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway
    Jim Dimitroulakos
    Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre and Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:4426s-4431s. 2006
    ..The combination of erlotinib and rosuvastatin has been proposed for a phase I/II study in advanced non-small cell lung carcinoma...
  5. pmc Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells
    Laurie Ma
    Centre for Cancer Therapeutics, The Ottawa Hospital Research Institute, Ontario, Canada
    PLoS ONE 7:e46055. 2012
    ..In recent studies, we demonstrated the ability of lovastatin, an inhibitor of mevalonate synthesis, to induce the Integrated Stress Response as well as inhibiting epidermal growth factor receptor (EGFR) activation...
  6. ncbi request reprint Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor
    Angela J Mantha
    Centre for Cancer Therapeutics and Medical Oncology, Ottawa Regional Cancer Centre, Ottawa Health Research Institute, 503 Smyth Road, Ottawa, Ontario, Canada K1H 1C4
    Clin Cancer Res 11:2398-407. 2005
    ..Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies...
  7. ncbi request reprint Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3
    Anna O'Brien
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Box 926, Ottawa, ON, K1H 8L6, Canada
    Anticancer Res 32:2679-88. 2012
    ..Activating transcription factor 3 (ATF3), a stress-inducible gene, is a regulator of cisplatin-induced cytotoxicity, and enhancement of the ATF3 expression potentiates this cytotoxicity...
  8. doi request reprint Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status
    Catia Cemeus
    Centre for Cancer Therapeutics, The Ottawa Health Research Institute and Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, ON, Canada, K1H 1C4
    J Neurooncol 90:9-17. 2008
    ..These studies demonstrate the potential of lovastatin to augment the cytotoxic effects of gefitinib and provide a rationale for combined statin/EGFR targeted therapies in glioblastoma patients...
  9. ncbi request reprint Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells
    Angela J Mantha
    Centre for Cancer Therapeutics, Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, Ontario, K1H 1C4, Canada
    J Cancer Res Clin Oncol 129:631-41. 2003
    ..In this study, we evaluated the potential of a number of chemotherapeutics that demonstrate activity in HNSCC, including an inhibitor of epidermal growth factor receptor (EGFR) to potentiate the cytotoxic effects of lovastatin...
  10. pmc Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3
    Carly St Germain
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Neoplasia 12:527-38. 2010
    ..This study identifies cisplatin as a MAPK pathway-dependent inducer of ATF3, whose expression influences cisplatin's cytotoxic effects...
  11. pmc Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors
    Tong T Zhao
    Centre for Cancer Therapeutics, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    PLoS ONE 5:e12563. 2010
    ..The vascular endothelial growth factor receptor (VEGFR) and EGFR share similar activation, internalization and downstream signaling characteristics...
  12. doi request reprint Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP
    Danielle E Arnold
    Centre for Cancer Therapeutics, The Ottawa Hospital Research Institute, Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, ON, K1H 1C4, Canada
    Mol Cell Biochem 345:1-11. 2010
    ..This study suggests the potential of combining these therapeutic approaches in EC and NB patients...
  13. doi request reprint Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection
    Fabrice Le Boeuf
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Int J Cancer 131:E204-15. 2012
    ..Taken together, these results demonstrate that HPV-infected cells are susceptible to oncolytic virus therapy and that this approach may represent a novel therapeutic approach in HPV positive CC and HNSCC patients...
  14. doi request reprint The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
    Johanne Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada
    Int J Cancer 124:806-15. 2009
    ..In summary, this study shows that low BRCA1 and ERCC1 expression correlate with improved survival in advanced OC and HDAC inhibition induces synergistic cytotoxicity with platinum in vitro...
  15. pmc miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels
    D Rice Honeywell
    Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada Departments of Biochemistry Microbiology and Immunology, University of Ottawa, Ontario, Canada
    PLoS ONE 8:e70515. 2013
    ..Our results suggest that miR-105 inhibits tumour cell proliferation and hence may represent a novel therapeutically relevant cellular target to inhibit tumour growth or a marker of aggressive tumours in prostate cancer patients. ..
  16. pmc The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
    Johanne I Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, 501 Smyth Road, Ottawa, K1H 8L6, Canada
    Cancer Cell Int 11:29. 2011
    ..abstract:..
  17. doi request reprint Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease
    Michael M Vickers
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
    Clin Exp Metastasis 29:123-32. 2012
    ..We have further found that an analysis of these five miRs expression levels in primary tumors significantly correlates with the presence of metastatic disease, making this a potential clinically useful prognostic tool...
  18. ncbi request reprint A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix
    Jennifer J Knox
    Departments of Medical Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, 5 218, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Eur J Cancer 41:523-30. 2005
    ..We conclude that the administration of lovastatin at 7.5 mg/kg/day for 21 consecutive days on a 28-day schedule is well tolerated in patients with good renal function and warrants further clinical evaluation...